Lung Cancer

Ivy Riano, MD, of Dartmouth Geisel School of Medicine, discusses the adoption of broader clinical trial eligibility in lung cancer, specifically for those with brain metastases or leptomeningeal disease.

Julie R. Brahmer, MD, MSc, FASCO, details practice-changing indications and notable data in the early-stage, neo(adjuvant), and metastatic NSCLC settings.

Daniel E. Haggstrom, MD, discusses future research directions within EGFR-and ALK-mutant non–small cell lung cancer.

The FDA has extended the PDUFA date of the BLA for zenocutuzumab in NRG1-positive non–small cell lung cancer and pancreatic cancer.

Here is your snapshot of all therapeutic options that the FDA approved in October 2024 spanning tumor types.

In case you missed any, read a recap of every episode of OncLive On Air that aired in October 2024.

This roundup includes exclusive insights from 23 clinicians and key data on the top abstracts coming out of the 2024 ESMO Annual Meeting.

Daniel E. Haggstrom, MD discusses the role of osimertinib for patients with unresectable EGFR-mutated non-small cell lung cancer.

An NDA seeking the approval of sacituzumab tirumotecan for EGFR-mutant non–small cell lung cancer is under review by the NMPA’s CDE.

First-line sugemalimab plus chemotherapy has received UK approval for metastatic NSCLC without EGFR-sensitizing mutations or ALK/ROS1/RET alterations.

For more first-hand insights, head over to our YouTube channel to watch Dr Markman discuss the inner workings of oncology: https://rb.gy/bvumdn.

IDE397 is the first MAT2A inhibitor to show clinical activity and safety in patients with MTAP-deletion urothelial cancer and non–small cell lung cancer.

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss progression patterns and therapies after lorlatinib in ALK-positive NSCLC.

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for NVL-655 in ALK-positive NSCLC and other ALK-positive solid tumors.

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss testing for ALK-positive and ROS1-positive non–small cell lung cancer.

Noman Ashraf, MD, discusses the evolving treatment landscape in non–small cell lung cancer following numerous regulatory approvals in the space.

Noman Ashraf, MD, discusses data with T-DXd in HER2-mutated and -overexpressing lung cancer populations and next steps with ADC combination therapies.

Nicolas Girard, MD, discusses finding from the LUMINOSITY trial in c-Met protein–overexpressing, EGFR wild-type, non–small cell lung cancer.

Zolbetuximab wins approval for CLDN18.2-positive gastric/GEJ cancer, TTFields joins the NSCLC armamentarium, and more of this week's top news in oncology.

Hidehito Horinouchi, MD, PhD, discusses safety data from the ALINA trial of adjuvant alectinib in ALK-positive non–small cell lung cancer.